Are there clinical features that would lead you to consider combining SBRT + immunotherapy in a high risk early stage NSCLC?

Topics: Radiation Oncology • Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer • SWOG

Answer from: Radiation Oncologist at Academic Institution

I currently only use SBRT + immunotherapy in medically inoperable, early-stage NSCLC on clinical trial, as it is not yet a standard of care for early-stage disease. There are several randomized phase 3 trials currently testing immunotherapy in this patient population, however. On SWOG/NRG S1914...

Comments

Medical Oncologist at NYU Winthrop Hospital
Only clinical trials.

Radiation Oncologist at Cancer Care Centers of Brevard
Clinical trial question.

Related Questions